

Safety and Immunogenicity of Recombinant Zoster Vaccine for Kidney Transplant Recipients

NCT06262776

Status	RECRUITING
Phase	Not Applicable
Sponsor	Central Adelaide Local Health Network Incorporated
Enrollment	120 participants

Key Eligibility Criteria

Inclusion (11)

- Single organ kidney transplant recipient, currently receiving a specific immunosuppression regimen:
- Calcineurin inhibitor (tacrolimus or cyclosporine), antimetabolite (mycophenolate derivative or azathioprine), and oral steroid (n = 30)
- Calcineurin inhibitor (tacrolimus or cyclosporine), mTOR inhibitor (sirolimus or everolimus), and oral steroid (n = 30)
- mTOR inhibitor (sirolimus or everolimus), antimetabolite (mycophenolate derivative or azathioprine), and oral steroid (n = 30)
- Aged >18 years
- ... and 6 more (see full listing online)

Exclusion (5)

- Unable or unwilling to provide informed consent to participate in the trial
- No previous infection with Varicella zoster (chickenpox)
- Known allergy to or intolerance of the contents of the SHINGRIX vaccine
- Current pregnancy
- For healthy household cohabitants, history of primary immunodeficiency, documented vaccine hypo-responsiveness, or active immunosuppressive therapy

Locations (1 total)

Royal Adelaide Hospital, Adelaide, South Australia, Australia